^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

KIT (KIT proto-oncogene, receptor tyrosine kinase)

i
Other names: KIT, KIT proto-oncogene receptor tyrosine kinase, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
1d
Extraluminal inflammatory fibroid polyp mimicking as wandering fibroid/GIST. (PubMed, BMJ Case Rep)
Extraluminal cases of IFPs are extremely rare in the literature. Recognising these unusual cases is crucial to prevent misdiagnosis, guide proper surgical management and reassure patients about their prognosis.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
2d
High-grade malignant peripheral nerve sheath tumor of the esophagus: a rare case highlighting the diagnostic value of immunohistochemistry. (PubMed, J Surg Case Rep)
This case report presents a highly unusual case of a primary high-grade malignant peripheral nerve sheath tumor (MPNST) of esophagus, a neoplasm of extreme rarity, with fewer than twenty histologically confirmed cases reported worldwide to date; detailing the successful management of this tumor through Orringer's transhiatal esophagectomy, complemented by comprehensive histopathologic and immunohistochemical evaluation. Our report emphasizes the crucial the role of immunohistochemistry, specifically the diagnostic value of S100, SOX10, and the exclusion of gastrointestinal stromal tumors markers (DOG1, CD117) in distinguishing MPNST, from morphologically similar esophageal submucosal tumors.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • SOX10 (SRY-Box 10) • ANO1 (Anoctamin 1)
2d
Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM-prognostic score (FCM-PS) for overall survival. (PubMed, Hemasphere)
Validation of the prognostic FCM-PS in an independent patient cohort confirmed good discrimination performance (AUC: 0.70). We introduce a unique, easy-to-use prognostic FCM-PS score (panel: CD45/CD34/CD117/CD33/CD19/CD123/HLA-DR) for OS in MDS, allowing refined risk stratification for IPSS-R subgroups.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
3d
New P2/3 trial
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
KIT exon 9 mutation
|
Stivarga (regorafenib) • NB003
4d
New trial
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • ANO1 (Anoctamin 1)
5d
Intra-abdominal Desmoid Tumors Mimicking Gastrointestinal Stromal Tumor (GIST) Recurrence: A Case Report. (PubMed, Cureus)
We report a case of a 60-year-old male who developed intra-abdominal desmoid tumors five years after undergoing laparoscopy and endoscopy cooperative surgery (LECS) for gastric GIST, followed by adjuvant imatinib therapy...Histopathological confirmation remains crucial for accurate diagnosis. Surgical resection is the primary treatment for symptomatic desmoid tumors, but given their high recurrence rate, long-term follow-up and a multidisciplinary approach are essential for optimal management.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CD34 (CD34 molecule)
|
imatinib
7d
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study. (PubMed, Blood Adv)
Eleven (10%) patients experienced TEAEs leading to death, of which 1 was deemed related to avapritinib by the principal investigator. With 4-year follow-up, avapritinib-treated patients with AdvSM experienced deep and durable responses and a favorable benefit-risk profile.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
Ayvakit (avapritinib)
7d
A Case of Metachronous Prostate Adenocarcinoma and Chromophobe Renal Cell Carcinoma in a Nigerian Male Patient: Diagnostic and Therapeutic Challenges. (PubMed, Cureus)
Two years later, a right renal mass was detected. While the initial histology favored oncocytoma, immunohistochemistry revealed strong cytokeratin (CK)7 expression with focal CD117 staining, confirming the eosinophilic subtype of ChRCC. This case illustrates the importance of thorough histopathologic work-up of renal lesions, the diagnostic value of immunohistochemistry, and the need for careful follow-up in patients with complex urologic histories.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
7d
Polydopamine-Coated Surfaces Promote Adhesion, Migration, Proliferation, Chemoresistance, Stemness, and Epithelial-Mesenchymal Transition of Human Prostate Cancer Cell Lines In Vitro via Integrin α2β1-FAK-JNK Signaling. (PubMed, Int J Mol Sci)
Pharmacological inhibition of integrin α2β1 (BTT-3033), FAK (PF573228) and JNK (SP600125) effectively abrogated PDA-induced malignant phenotypes and restored chemosensitivity to cabazitaxel, cisplatin, docetaxel, curcumin, and enzalutamide. Collectively, these findings identify PDA-coated surfaces as a simple, efficient, and reductionist in vitro platform for studying adhesion-mediated signaling and phenotypic plasticity in PC cells, while acknowledging that further validation in three-dimensional (3D) and patient-derived models will be required to establish in vivo relevance.
Preclinical • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CD44 (CD44 Molecule) • MMP2 (Matrix metallopeptidase 2) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • MMP9 (Matrix metallopeptidase 9) • NANOG (Nanog Homeobox)
|
cisplatin • docetaxel • Xtandi (enzalutamide) • cabazitaxel • PF-573228 • SP600125
7d
Malignant Melanoma: Landscape of Molecular Markers. (PubMed, Biomedicines)
This study is limited due to a small cohort and limited available clinical data. Larger cohort studies and prospective clinical trials are necessary to validate and explore the interplay between molecular and immune biomarkers as well as general biological mechanism in paving therapeutic way in melanoma.
Journal • PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • PMS2 (PMS1 protein homolog 2) • TSC2 (TSC complex subunit 2) • NOTCH3 (Notch Receptor 3)
|
BRAF mutation • NRAS mutation • KIT mutation
7d
Aberrant CD25 and Increased CD123 Expression Are Common in Acute Myeloid Leukemia with KMT2A Partial Tandem Duplication and Are Associated with FLT3 Internal Tandem Duplication. (PubMed, Cancers (Basel))
AML with KMT2A-PTD shows distinctive immunophenotypic features with increased CD123 and aberrant CD25 expression, both associated with FLT3-ITD. These markers may have diagnostic and therapeutic relevance in this AML subtype.
Journal • IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD34 (CD34 molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
FLT3-ITD mutation • IL2RA expression
8d
Age-dependent clinical, molecular, and prognostic differences in patients with AML: a retrospective study. (PubMed, Hematology)
This study revealed that patients aged ≥50 years displayed more complex genetic aberration profiles and experienced significantly poorer prognoses compared to their younger counterparts. These findings provided novel insights for optimizing treatment strategies for middle-aged and elderly AML patients in the Chinese population.
Retrospective data • Journal
|
TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • WT1 (WT1 Transcription Factor) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
TP53 mutation • KIT mutation • Chr del(5q) • CBFB-MYH11 fusion
|
Venclexta (venetoclax)